{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:32:50Z","timestamp":1770143570265,"version":"3.49.0"},"reference-count":15,"publisher":"The Pediatric Pharmacy Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:p>Elexacaftor\/tezacaftor\/ivacaftor (ELX\/TEZ\/IVA) was given US Food and Drug Administration approval based on its therapeutic benefits to treat patients with cystic fibrosis (CF) who had at least 1 allele of the CF transmembrane conductance regulator (CFTR) with phenylalanine deleted at position 508 (F508del). The increase in genotyping studies has increased the frequency of use of CFTR modulators; however, severe allergic reactions to CFTR modulators have also been described. It is critical to avoid the offending medication and select alternative treatments while dealing with drug allergies. Drug desensitization may be taken into consideration in situations where there is no other option. This article describes home desensitization treatment for a patient with CF who developed a maculopapular rash following CFTR modulator medication. There are currently no alternative drugs for CFTR modulators, which are crucial for patients with CF, and limited experience is available with allergic reactions to these drugs. It is important to establish desensitization protocols in order to control drug reactions to CFTR modulators, which are vital for individuals with CF.<\/jats:p>","DOI":"10.5863\/1551-6776-29.5.539","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T10:52:46Z","timestamp":1728903166000},"page":"539-543","source":"Crossref","is-referenced-by-count":1,"title":["Successful Desensitization With ELX\/TEZ\/IVA"],"prefix":"10.5863","volume":"29","author":[{"given":"Dilara Fatma Kocacik","family":"Uygun","sequence":"first","affiliation":[{"name":"Pediatric Allergy-Immunology Department (DFKU, MAK, AB), Akdeniz University School of Medicine, Pediatric Pulmonology Department (BB, AEB), Akdeniz University School of Medicine, Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Akif","family":"Kaya","sequence":"additional","affiliation":[{"name":"Pediatric Allergy-Immunology Department (DFKU, MAK, AB), Akdeniz University School of Medicine, Pediatric Pulmonology Department (BB, AEB), Akdeniz University School of Medicine, Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bet\u00fcl","family":"Bankoglu","sequence":"additional","affiliation":[{"name":"Pediatric Allergy-Immunology Department (DFKU, MAK, AB), Akdeniz University School of Medicine, Pediatric Pulmonology Department (BB, AEB), Akdeniz University School of Medicine, Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdurrahman Erdem","family":"Basaran","sequence":"additional","affiliation":[{"name":"Pediatric Allergy-Immunology Department (DFKU, MAK, AB), Akdeniz University School of Medicine, Pediatric Pulmonology Department (BB, AEB), Akdeniz University School of Medicine, Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fen","family":"Bingol","sequence":"additional","affiliation":[{"name":"Pediatric Allergy-Immunology Department (DFKU, MAK, AB), Akdeniz University School of Medicine, Pediatric Pulmonology Department (BB, AEB), Akdeniz University School of Medicine, Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"issue":"10290","key":"2024101410523631300_i2331-348X-29-5-539-b01","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2024101410523631300_i2331-348X-29-5-539-b02","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/cod.14002","article-title":"Toxic epidermal necrolysis induced by cystic \u00adfibrosis transmembrane conductance regulator modulators","volume":"86","author":"Mederos-Luis","year":"2022","journal-title":"Contact Dermatitis"},{"issue":"18","key":"2024101410523631300_i2331-348X-29-5-539-b03","doi-asserted-by":"crossref","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"2024101410523631300_i2331-348X-29-5-539-b04","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"10212","key":"2024101410523631300_i2331-348X-29-5-539-b05","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"2024101410523631300_i2331-348X-29-5-539-b06","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2024101410523631300_i2331-348X-29-5-539-b07","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaci.2020.05.041","article-title":"Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4(+) T lymphocytes","volume":"147","author":"Roehmel","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2024101410523631300_i2331-348X-29-5-539-b08","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"issue":"2","key":"2024101410523631300_i2331-348X-29-5-539-b09","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2024101410523631300_i2331-348X-29-5-539-b10","doi-asserted-by":"crossref","first-page":"e04116","DOI":"10.1002\/ccr3.4116","article-title":"Novel reaction to new cystic fibrosis medication Trikafta","volume":"9","author":"Stashower","year":"2021","journal-title":"Clin Case Rep"},{"issue":"5","key":"2024101410523631300_i2331-348X-29-5-539-b11","first-page":"467","article-title":"If At First You Don't Succeed, Trikafta Again","volume":"27","author":"Loyd","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"11","key":"2024101410523631300_i2331-348X-29-5-539-b12","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1002\/ppul.25072","article-title":"Serum sickness-like reaction following initiation of elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"55","author":"Brennan","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"2024101410523631300_i2331-348X-29-5-539-b13","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/ppul.25437","article-title":"CFTR modulator drug desensitization: Preserving the hope of long term improvement","volume":"56","author":"Leonhardt","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"2024101410523631300_i2331-348X-29-5-539-b14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ppul.24319","article-title":"Ivacaftor drug desensitization","volume":"54","author":"Patterson","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"7","key":"2024101410523631300_i2331-348X-29-5-539-b15","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/ppul.25938","article-title":"At-home compounding preparation of slow desensitization of elexacaftor\/tezacaftor\/ivacaftor for delayed hypersensitivity rash","volume":"57","author":"Muirhead","year":"2022","journal-title":"Pediatr Pulmonol"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/5\/539\/3441584\/i2331-348x-29-5-539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/5\/539\/3441584\/i2331-348x-29-5-539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:41:47Z","timestamp":1738780907000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/5\/article-p539.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,14]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-29.5.539","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}